ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Postmenopausal Vaginal Atrophy Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-4Z2965
Home | Market Reports | Health| Reproductive Health
Global Postmenopausal Vaginal Atrophy Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Postmenopausal Vaginal Atrophy Drugs Market Research Report 2025

Code: QYRE-Auto-4Z2965
Report
September 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
EndoCeutics
Pfizer Inc
Company
Shionogi
Aspen Pharma
Novo Nordisk
Teva Pharmaceutical Industries
Duchesnay USA
Millicent Pharma

Postmenopausal Vaginal Atrophy Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Postmenopausal Vaginal Atrophy Drugs Market

Postmenopausal Vaginal Atrophy Drugs Market

The global market for Postmenopausal Vaginal Atrophy Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs.
The Postmenopausal Vaginal Atrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Postmenopausal Vaginal Atrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Postmenopausal Vaginal Atrophy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Postmenopausal Vaginal Atrophy Drugs Market Report

Report Metric Details
Report Name Postmenopausal Vaginal Atrophy Drugs Market
CAGR 5%
Segment by Type
Segment by Application
  • Offline Stores
  • Online Stores
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Aspen Pharma, Novo Nordisk, Teva Pharmaceutical Industries, Millicent Pharma, Duchesnay USA, Endoceutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Postmenopausal Vaginal Atrophy Drugs Market report?

Ans: The main players in the Postmenopausal Vaginal Atrophy Drugs Market are Pfizer, Aspen Pharma, Novo Nordisk, Teva Pharmaceutical Industries, Millicent Pharma, Duchesnay USA, Endoceutics

What are the Application segmentation covered in the Postmenopausal Vaginal Atrophy Drugs Market report?

Ans: The Applications covered in the Postmenopausal Vaginal Atrophy Drugs Market report are Offline Stores, Online Stores

What are the Type segmentation covered in the Postmenopausal Vaginal Atrophy Drugs Market report?

Ans: The Types covered in the Postmenopausal Vaginal Atrophy Drugs Market report are Creams, Suppositories, Tablets, Rings

Recommended Reports

Gynecology & Hormones

Incontinence & Rejuvenation

Female Health & Therapy

1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Product Definition
1.2 Postmenopausal Vaginal Atrophy Drugs by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Creams
1.2.3 Suppositories
1.2.4 Tablets
1.2.5 Rings
1.3 Postmenopausal Vaginal Atrophy Drugs by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Value by Application (2024 VS 2031)
1.3.2 Offline Stores
1.3.3 Online Stores
1.4 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2020-2031
1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2020-2031
1.4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Postmenopausal Vaginal Atrophy Drugs Market Competition by Manufacturers
2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Postmenopausal Vaginal Atrophy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Product Type & Application
2.7 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Date of Enter into This Industry
2.8 Global Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends
2.8.1 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue
2.8.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Postmenopausal Vaginal Atrophy Drugs Market Scenario by Region
3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2020-2031
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2020-2025
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2026-2031
3.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2020-2031
3.3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2020-2025
3.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2026-2031
3.4 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.4.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2031)
3.4.3 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.5.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2031)
3.5.3 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.7.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2031)
3.7.3 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2020-2031)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2020-2025)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2026-2031)
4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2020-2031)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2020-2031)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2020-2025)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2026-2031)
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2020-2031)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2020-2025)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2026-2031)
5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2020-2031)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2020-2031)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2020-2025)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2026-2031)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Aspen Pharma
6.2.1 Aspen Pharma Company Information
6.2.2 Aspen Pharma Description and Business Overview
6.2.3 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.2.5 Aspen Pharma Recent Developments/Updates
6.3 Novo Nordisk
6.3.1 Novo Nordisk Company Information
6.3.2 Novo Nordisk Description and Business Overview
6.3.3 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.3.5 Novo Nordisk Recent Developments/Updates
6.4 Teva Pharmaceutical Industries
6.4.1 Teva Pharmaceutical Industries Company Information
6.4.2 Teva Pharmaceutical Industries Description and Business Overview
6.4.3 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.4.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.5 Millicent Pharma
6.5.1 Millicent Pharma Company Information
6.5.2 Millicent Pharma Description and Business Overview
6.5.3 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.5.5 Millicent Pharma Recent Developments/Updates
6.6 Duchesnay USA
6.6.1 Duchesnay USA Company Information
6.6.2 Duchesnay USA Description and Business Overview
6.6.3 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.6.5 Duchesnay USA Recent Developments/Updates
6.7 Endoceutics
6.7.1 Endoceutics Company Information
6.7.2 Endoceutics Description and Business Overview
6.7.3 Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.7.5 Endoceutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Postmenopausal Vaginal Atrophy Drugs Industry Chain Analysis
7.2 Postmenopausal Vaginal Atrophy Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process Analysis
7.4 Postmenopausal Vaginal Atrophy Drugs Sales and Marketing
7.4.1 Postmenopausal Vaginal Atrophy Drugs Sales Channels
7.4.2 Postmenopausal Vaginal Atrophy Drugs Distributors
7.5 Postmenopausal Vaginal Atrophy Drugs Customer Analysis
8 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
8.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
8.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers
8.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
8.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
EndoCeutics
Pfizer Inc
Company
Shionogi
Aspen Pharma
Novo Nordisk
Teva Pharmaceutical Industries
Duchesnay USA
Millicent Pharma
List of Tables
 Table 1. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Postmenopausal Vaginal Atrophy Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Postmenopausal Vaginal Atrophy Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Postmenopausal Vaginal Atrophy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Postmenopausal Vaginal Atrophy Drugs Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Aspen Pharma Company Information
 Table 76. Aspen Pharma Description and Business Overview
 Table 77. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product
 Table 79. Aspen Pharma Recent Developments/Updates
 Table 80. Novo Nordisk Company Information
 Table 81. Novo Nordisk Description and Business Overview
 Table 82. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product
 Table 84. Novo Nordisk Recent Developments/Updates
 Table 85. Teva Pharmaceutical Industries Company Information
 Table 86. Teva Pharmaceutical Industries Description and Business Overview
 Table 87. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product
 Table 89. Teva Pharmaceutical Industries Recent Developments/Updates
 Table 90. Millicent Pharma Company Information
 Table 91. Millicent Pharma Description and Business Overview
 Table 92. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product
 Table 94. Millicent Pharma Recent Developments/Updates
 Table 95. Duchesnay USA Company Information
 Table 96. Duchesnay USA Description and Business Overview
 Table 97. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product
 Table 99. Duchesnay USA Recent Developments/Updates
 Table 100. Endoceutics Company Information
 Table 101. Endoceutics Description and Business Overview
 Table 102. Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Endoceutics Postmenopausal Vaginal Atrophy Drugs Product
 Table 104. Endoceutics Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Postmenopausal Vaginal Atrophy Drugs Distributors List
 Table 108. Postmenopausal Vaginal Atrophy Drugs Customers List
 Table 109. Postmenopausal Vaginal Atrophy Drugs Market Trends
 Table 110. Postmenopausal Vaginal Atrophy Drugs Market Drivers
 Table 111. Postmenopausal Vaginal Atrophy Drugs Market Challenges
 Table 112. Postmenopausal Vaginal Atrophy Drugs Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Postmenopausal Vaginal Atrophy Drugs
 Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type: 2024 & 2031
 Figure 4. Creams Product Picture
 Figure 5. Suppositories Product Picture
 Figure 6. Tablets Product Picture
 Figure 7. Rings Product Picture
 Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application: 2024 & 2031
 Figure 10. Offline Stores
 Figure 11. Online Stores
 Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales (2020-2031) & (K Units)
 Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 16. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
 Figure 17. Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers in 2024
 Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players: Market Share by Revenue in Postmenopausal Vaginal Atrophy Drugs in 2024
 Figure 20. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2020-2031)
 Figure 23. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2020-2031)
 Figure 27. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2020-2031)
 Figure 35. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2020-2031)
 Figure 57. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2020-2031)
 Figure 60. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 61. Postmenopausal Vaginal Atrophy Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Postmenopausal Vaginal Atrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Postmenopausal Vaginal Atrophy PVA Therapeutics Market Insights Forecast to 2030
Postmenopausal Vaginal Atrophy PVA Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vulvar and Vaginal Atrophy Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vaginal Rejuvenation Market Research Report 2024
Global Vasomotor Symptoms of Menopause Treatment Market Research Report 2024
Global Post Menopausal Osteoporosis Drug Market Research Report 2024
Vaginal and Vulval Inflammatory Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vaginal Antifungal Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Vulvovaginal Rejuvenation Laser Market Research Report 2024
Global Vaginitis Therapeutics Market Insights Forecast to 2030
Global Female Urinary Incontinence Treatment Market Research Report 2024
Global Postmenopausal Breast Cancer Treatment Drugs Market Research Report 2024
Drugs for Vaginal Fungal Infections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Menopause Hormonal Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Menopause Supplement Market Research Report 2024
Vulvodynia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Menopausal Hot Flashes Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Menopause Hormonal Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Menopause Drugs Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions